Pharmacology · Diabetes Pharmacology

GLP-1/GIP Dual Agonism, Weight Pharmacology, and Emerging Agents

Tirzepatide, pipeline agents, and expanded indications

Tirzepatide adds GIP receptor co-agonism to GLP-1 receptor agonism — GIP amplifies postprandial insulin secretion through a distinct G-protein pathway and appears to enhance GLP-1 sensitivity through receptor cross-talk at the hypothalamic level; the clinical result is superior HbA1c lowering (2.46% vs. 2.09% for semaglutide 1 mg in SURPASS-2) and greater weight loss (15–22% in diabetic patients, up to 22% in obesity), compared to GLP-1 monotherapy at equivalent doses.
The weight loss achievable with pharmacological GLP-1 and GIP receptor agonism is categorically different from prior anti-obesity agents — tirzepatide produced approximately 22% body weight reduction in SURMOUNT-1 (non-diabetic obesity), approaching the efficacy of bariatric surgery; this magnitude of weight loss translates into meaningful reductions in cardiometabolic risk factors including blood pressure, lipids, and insulin resistance beyond what glycemic control alone would achieve.
Weight loss with these agents is not sustained after discontinuation — clinical trials consistently show near-complete weight regain within 12 months of stopping the drug; this is because GLP-1 and GIP receptor agonists lower the hypothalamic body weight set point during treatment but do not reprogram it permanently; clinically, these drugs should be framed as chronic therapies analogous to antihypertensives — they treat the condition while taken but do not cure the underlying biology.
The pipeline of incretin-based agents extends the weight loss ceiling further: retatrutide adds glucagon receptor agonism (which increases energy expenditure through thermogenesis) to GLP-1/GIP dual agonism and produced approximately 24% weight loss in phase 2; cagrisema combines amylin analog cagrilintide with semaglutide to produce complementary satiety signals through amylin receptors in the area postrema; orforglipron is an oral small-molecule GLP-1 receptor agonist that does not require an absorption enhancer, potentially enabling lower manufacturing cost and broader access.
Tirzepatide's approved indications now extend beyond type 2 diabetes and obesity: the SYNERGY-NASH trial showed 62% resolution of metabolic dysfunction-associated steatohepatitis (MASH/NASH) versus 19% with placebo, leading to FDA approval for this indication; the SUMMIT trial demonstrated reduced worsening heart failure events in HFpEF with obesity — expanding the therapeutic reach of incretin pharmacology into organ-specific disease states beyond glycemic and weight management.

Abbreviations: GIP = glucose-dependent insulinotropic polypeptide · GLP-1 = glucagon-like peptide-1 · MASH = metabolic dysfunction-associated steatohepatitis · HFpEF = heart failure with preserved ejection fraction · MACE = major adverse cardiovascular events · T2DM = type 2 diabetes mellitus · HbA1c = glycated hemoglobin

Key Efficacy Data

2.46%

HbA1c reduction — tirzepatide 15 mg (SURPASS-2)

2.09%

HbA1c reduction — semaglutide 1 mg (SURPASS-2 comparator)

~22%

Body weight reduction — tirzepatide (SURMOUNT-1, non-diabetic)

62%

MASH resolution rate — tirzepatide (SYNERGY-NASH)

Mechanism Comparison — Semaglutide vs. Tirzepatide

GLP-1 Monotherapy

Semaglutide

GLP-1 receptor agonism only
Glucose-dependent insulin secretion ↑; glucagon suppressed
Appetite suppressed via hypothalamic GLP-1 receptors
Gastric emptying slowed
Weight loss: 10–15% (diabetes); up to 17% (obesity, STEP trials)
MACE reduction established: LEADER (liraglutide), SUSTAIN-6, PIONEER-6

GIP + GLP-1 Dual Agonism

Tirzepatide

Dual GIP receptor + GLP-1 receptor co-agonism — additive and synergistic effects
GIP amplifies insulin secretion via distinct G-protein pathway; enhances GLP-1 hypothalamic sensitivity
Superior postprandial glucose control vs. GLP-1 monotherapy
Weight loss: 15–22% in T2DM; up to 22% in non-diabetic obesity (SURMOUNT-1)
SURPASS-CVOT: MACE superiority demonstrated over dulaglutide
Approved indications: T2DM, obesity, MASH, and HFpEF with obesity

Pipeline Incretin Agents

Agent	Class	Receptor Targets	Phase	Key Data
Retatrutide	Triple agonist	GLP-1 + GIP + Glucagon receptors	Phase 3	~24% weight loss in phase 2; glucagon adds energy expenditure via thermogenesis
CagriSema	Amylin + GLP-1 combination	Amylin receptor + GLP-1 receptor	Phase 3	~25% weight loss; amylin acts centrally in area postrema — complementary satiety pathway
Orforglipron	Oral small molecule	GLP-1 receptor only	Phase 3	~9–10% weight loss; no special absorption enhancer needed; lower cost potential; fully oral dosing

Expanded Indications and Weight Pharmacology

Beyond Glucose and Weight

Tirzepatide — Expanded Indications

MASH (SYNERGY-NASH): 62% histological resolution vs. 19% placebo — FDA approved for this indication
HFpEF + obesity (SUMMIT): reduced worsening heart failure events and improved functional capacity
SURPASS-CVOT: MACE superiority over dulaglutide — first GLP-1 agonist class superiority data vs. another GLP-1 agent
Obstructive sleep apnea: trials ongoing — preliminary weight-driven improvements noted

Chronic Therapy Principle

Weight Loss — What Stops When You Stop

GLP-1/GIP receptor agonists lower the hypothalamic defended body weight set point during therapy
Weight loss is NOT maintained after discontinuation — essentially complete weight regain occurs within 12 months of stopping
These are chronic therapies, not short-term interventions — analogous to antihypertensives: treat but do not cure
Patients and prescribers must understand this before initiating: the expectation of indefinite therapy is clinically essential

Weight Loss Pharmacology — The Set Point Model

The hypothalamus defends a genetically and neurally encoded body weight set point through redundant feeding circuits involving melanocortin-4 receptors, NPY/AgRP neurons, and POMC neurons. GLP-1 and GIP receptors in the hypothalamus and area postrema modulate these circuits, lowering the defended set point during drug exposure — which is why appetite suppression and weight loss occur and are maintained throughout treatment.

When the drug is discontinued, the defended set point returns to baseline and appetite rebounds. This biology explains the consistent finding across multiple trial extension studies that weight regain after stopping GLP-1 agonist therapy is nearly complete within 12 months. The clinical implication is straightforward: obesity pharmacotherapy is chronic disease management, not a short-course intervention, and treatment plans should reflect this from the outset.

Suggested References

Author / Source	Title	Publication
Katzung BG, ed.	Basic and Clinical Pharmacology, 15th ed. — Chapter 41: Pancreatic Hormones and Antidiabetic Drugs	McGraw-Hill; 2021
Brunton L, Knollmann B, Hilal-Dandan R, eds.	Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th ed. — Chapter 45: Endocrine Pancreas and Pharmacotherapy of Diabetes Mellitus and Hypoglycemia	McGraw-Hill; 2023
Coskun T et al	LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus	Mol Metab. 2018;18:3–14
Nauck MA, D’Alessio DA	Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes	Cardiovasc Diabetol. 2022;21(1):169
Frias JP et al (SURPASS-2)	Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes	N Engl J Med. 2021;385(6):503–515
Jastreboff AM et al (SURMOUNT-1)	Tirzepatide once weekly for the treatment of obesity	N Engl J Med. 2022;387(3):205–216
Nicholls SJ et al (SURPASS-CVOT)	Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes	N Engl J Med. 2025;393(24):2409–2420
Cone RD	Anatomy and regulation of the central melanocortin system	Nat Neurosci. 2005;8(5):571–578
Drucker DJ	GLP-1 physiology informs the pharmacotherapy of obesity	Mol Metab. 2022;57:101351
Jastreboff AM et al (retatrutide)	Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial	N Engl J Med. 2023;389(6):514–526
Frias JP et al (CagriSema)	Efficacy and safety of co-administered cagrilintide 2.4 mg with semaglutide 2.4 mg in type 2 diabetes	Lancet. 2023;402(10403):720–730
Frias JP et al (orforglipron)	Efficacy and safety of oral orforglipron in patients with type 2 diabetes	Lancet. 2023;402(10400):472–483
Loomba R et al (SYNERGY-NASH)	Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis	N Engl J Med. 2024;391(4):299–310
Packer M et al (SUMMIT)	Tirzepatide for heart failure with preserved ejection fraction and obesity	N Engl J Med. 2025;392(5):427–437
Garvey WT et al (SURMOUNT-2)	Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes	Lancet. 2023;402(10402):613–626
Kosiborod MN et al	Semaglutide in patients with heart failure with preserved ejection fraction and obesity	N Engl J Med. 2023;389(12):1069–1084
American Diabetes Association	Standards of Care in Diabetes—2024	Diabetes Care. 2024;47(Suppl 1):S1–S321